Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:605177's ROE % is ranked better than 73.84% of 1250
companies
in the Biotechnology industry
Industry Median: -38.615
vs SHSE:605177: -6.07
Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Zhejiang East-Asia Pharmaceutical Co ROE % Related Terms
Zhejiang East-Asia Pharmaceutical Co ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zhejiang East-Asia Pharmaceutical Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang East-Asia Pharmaceutical Co ROE % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) has a ROE % of -7.87% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Zhejiang East-Asia Pharmaceutical Co and its competitors. According to the industry distribution chart, Zhejiang East-Asia Pharmaceutical Co ranks #327 out of 1250 companies in the Biotechnology industry, placing it in the top 26.2%.
Is Zhejiang East-Asia Pharmaceutical Co's ROE % too high?
Zhejiang East-Asia Pharmaceutical Co's current ROE % is -7.87%. Based on the distribution chart, Zhejiang East-Asia Pharmaceutical Co ranks #327 out of 1250 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zhejiang East-Asia Pharmaceutical Co has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang East-Asia Pharmaceutical Co's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhejiang East-Asia Pharmaceutical Co ranks #327 out of 1250 companies for ROE %. This puts Zhejiang East-Asia Pharmaceutical Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Zhejiang East-Asia Pharmaceutical Co and its competitors. Zhejiang East-Asia Pharmaceutical Co's current ROE % is -7.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang East-Asia Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥12.42, compared to a current price of ¥15.10 — trading 21.6% above its estimated fair value. The current ROE % is -7.87%. Zhejiang East-Asia Pharmaceutical Co's overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Zhejiang East-Asia Pharmaceutical Co (SHSE:605177), the current ROE % is -7.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥15.10 is trading 21.6% above its estimated GF Value™ of ¥12.42.
GuruFocus considers Zhejiang East-Asia Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:605177:
ROE %: -7.87%
GF Value™: ¥12.42 vs. price of ¥15.10 (21.6% above fair value)
No single metric tells the full story. See the SHSE:605177 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang East-Asia Pharmaceutical Co Business Description
Zhejiang East-Asia Pharmaceutical Co Ltd is mainly engaged in the production of bulk pharmaceutical chemicals, tablets, granules and capsules. The company's main products are: Ofloxacin, levofloxacin, loratadine hydrochloride, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, piperazine, ticlazole and so on.
57GF Score
Get the complete analysis for SHSE:605177
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605177 has been successfully added to your 
